Zogenix and Astellas to co-promote migraine injectable

Share this article:
Zogenix and Astellas to co-promote migraine injectable
Zogenix and Astellas to co-promote migraine injectable
California-based Zogenix announced a partnership with Astellas to co-promote Sumavel DosePro, a subcutaneous injection for migraine relief.  

Approved in July, Sumavel DosePro (sumatriptan injection) will be commercially available in January 2010, with “a broad mix of marketing elements” to follow, according to Catherine O'Connor, senior director, commercial communications at Zogenix.

Roughly 100 sales reps from Zogenix will focus on detailing neurologists, with Astellas's sales force tasked with primary care physicians, O'Connor said, adding that the specifics of the campaign are still being worked out. Compensation for sales forces at Zogenix and Astellas will be based on performance within their respective prescriber audiences, according to a company release. There will be consumer marketing elements, O'Connor verified. Zogenix is responsible for manufacturing and distribution of the product.

Edelman is handling public relations and digital work on Sumavel DosePro, with The CementWorks assigned to other marketing materials, according to O'Connor.

Sumavel DosePro is billed as a “first-of-its-kind needle-free delivery system,” indicated for the acute treatment of migraine attacks and cluster headache episodes. Sumatriptan is also the active ingredient in GlaxoSmithKline's Imitrex injection, which faced a patent expiry last February. O'Connor wrote in an email that Sumavel DosePro differs from Imitrex by way of its patented needle-free delivery system, which is a pre-filled, single use product.

Nearly 30 million Americans, primarily women ages 25 to 40, suffer from migraines, according to National Headache Foundation data cited in the release.

Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.